Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 90 articles: HTML format

Single Articles

March 2026
1. LIU Y, Cao J, Yu H, Sun Q, et al
   Dual Role of PSMB9 Linking Immune Activation and Tumor Adaptation in Hepatocellular Carcinoma With Therapeutic and Prognostic Implications.
   Anticancer Res. 2026;46:1389-1410.
   PubMed     Abstract available
   
   
   
2. MOHRI K, Nagai H, Mukozu T, Matsui T, et al
   Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights.
   Anticancer Res. 2026;46:1545-1556.
   PubMed     Abstract available
   
   
   
3. MUTO H, Kuzuya T, Tachi Y, Nagano Y, et al
   Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab.
   Anticancer Res. 2026;46:1609-1618.
   PubMed     Abstract available
   
   
   
4. TSUJI M, Kobayashi K, Kawakami K, Fukuda N, et al
   Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib Therapy.
   Anticancer Res. 2026;46:1651-1659.
   PubMed     Abstract available
   
   
   
5. MAIMON O, Nisman B, Ben-David I, Kuznetz A, et al
   Autologous Tumor Vaccination in Melanoma and Colon Cancer Patients With Recurrent Liver Metastases: A Case Series.
   Anticancer Res. 2026;46:1569-1575.
   PubMed     Abstract available
   
   
   February 2026
6. MATSUI S, Kato Y, Ohgi K, Ashida R, et al
   Clinical Relevance of the CALLY Index in Prognostic Stratification of Intrahepatic Cholangiocarcinoma.
   Anticancer Res. 2026;46:963-974.
   PubMed     Abstract available
   
   
   January 2026
7. OKUYAMA S, Ueno M, Oi T, Nishikawa S, et al
   A Prospective Study of Olanzapine and Aprepitant for CINV in Cisplatin-HAIC for Hepatocellular Carcinoma (PROACT).
   Anticancer Res. 2026;46:395-405.
   PubMed     Abstract available
   
   
   December 2025
8. WU J, Fu X, Chang S, Su W, et al
   Homochlorcyclizine Dihydrochloride Inhibits Hepatocellular Carcinoma Progression and Cancer Stem Cell Properties.
   Anticancer Res. 2025;45:5465-5475.
   PubMed     Abstract available
   
   
   
9. KUWANO A, Tanaka K, Hamamoto T, Kurosaka K, et al
   Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab-Durvalumab.
   Anticancer Res. 2025;45:5697-5708.
   PubMed     Abstract available
   
   
   
10. HAYASHI K, Suzuki O, Ichise K, Uchida H, et al
    Carbon-ion Radiotherapy for Hepatocellular Cancer Arising in Transplanted Liver Tissue.
    Anticancer Res. 2025;45:5807-5812.
    PubMed     Abstract available
    
    
    
11. FURUKAWA K, Haruki K, Shirai Y, Onda S, et al
    Pulmonary Emphysema Assessed by the Goddard Score Predicts Outcomes After Hepatic Resection for Colorectal Liver Metastases.
    Anticancer Res. 2025;45:5765-5772.
    PubMed     Abstract available
    
    
    
12. TANIOKA N, Seo S, Kawanishi Y, Fujisawa K, et al
    Precise Anatomical Resection of the Left Lateral Section Using Extrahepatic Glissonean Approach and Fluorescence Guidance.
    Anticancer Res. 2025;45:5689-5695.
    PubMed     Abstract available
    
    
    November 2025
13. XUE X, Huang Q, Bai X, Yang J, et al
    Combination Strategy of Arsenic Trioxide and its Metabolite For Leukemia Treatment and Modulation of Endoplasmic Reticulum-mediated Hepatotoxicity.
    Anticancer Res. 2025;45:4941-4958.
    PubMed     Abstract available
    
    
    October 2025
14. TAKAHASHI H, Kojima D, Miyasaka Y, Wada H, et al
    Neoadjuvant Chemotherapy for Initially Resectable Metachronous Colorectal Cancer Liver Metastases Is Associated With Early Postoperative Relapse.
    Anticancer Res. 2025;45:4547-4564.
    PubMed     Abstract available
    
    
    
15. KITAOKA A, Oura K, Fujita K, Sasaki K, et al
    Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:4211-4229.
    PubMed     Abstract available
    
    
    
16. TAKEDA S, Namisaki T, Koizumi A, Takaya H, et al
    The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:4493-4507.
    PubMed     Abstract available
    
    
    
17. KARASHIMA R, Masuda T, Nagayama Y, Adachi Y, et al
    Hepatic Pseudolipoma Mimicking Fat-containing Malignant Liver Tumor: A Case of Migration from the Pelvic Cavity.
    Anticancer Res. 2025;45:4653-4658.
    PubMed     Abstract available
    
    
    
18. KUWANO A, Yada M, Tanaka K, Hamomoto T, et al
    Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study.
    Anticancer Res. 2025;45:4627-4636.
    PubMed     Abstract available
    
    
    September 2025
19. HO WH, Jhuang YC, Liang JA, Lin YC, et al
    Impact of Tumor Size on Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiotherapy.
    Anticancer Res. 2025;45:3961-3970.
    PubMed     Abstract available
    
    
    
20. KOMORI H, Masuda T, Kurano R, Sugita H, et al
    A Rare Case of Fibrolamellar Hepatocellular Carcinoma in an Elderly Patient With Prior Hepatitis C Achieving Sustained Virologic Response.
    Anticancer Res. 2025;45:4047-4055.
    PubMed     Abstract available
    
    
    August 2025
21. SAKAI H, Goto Y, Fukutomi S, Arai S, et al
    Standardized Technique for Minimally Invasive Right Posterior Sectionectomy for Hepatocellular Carcinoma: A Propensity Score-matched Study.
    Anticancer Res. 2025;45:3497-3510.
    PubMed     Abstract available
    
    
    
22. FUKUTOMI S, Sakai H, Goto Y, Hashimoto K, et al
    Short- and Long-term Outcomes of Laparoscopic Versus Open Repeat Hepatectomy for Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:3523-3530.
    PubMed     Abstract available
    
    
    July 2025
23. SHIM HJ, Park MS, Bae WK, Cho SH, et al
    ITGAV Regulation of LGALS3BP-JUNB Axis Facilitates the Cell-to-Cell Adhesion and Invasiveness of Hepatic Cancer Cells.
    Anticancer Res. 2025;45:2997-3008.
    PubMed     Abstract available
    
    
    
24. MUTO-FUJITA E, Yamaoka B, Abe N, Fujiwara K, et al
    Ketone Bodies Inhibit Growth of Hepatoblastoma and Rhabdoid Tumor of the Kidney Cells.
    Anticancer Res. 2025;45:3089-3097.
    PubMed     Abstract available
    
    
    
25. LIN KH, Tsai CJ, Chen YT, Lin RF, et al
    Amentoflavone Enhances the Anti-tumor Activity of Regorafenib by Promoting Apoptosis and Inhibiting NF-kappaB-mediated Metastasis in Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:3045-3058.
    PubMed     Abstract available
    
    
    April 2025
26. KUWANO A, Yada M, Tanaka K, Takahira J, et al
    Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:1713-1721.
    PubMed     Abstract available
    
    
    
27. MASUDA T, Beppu T, Miyamoto H, Nagayama Y, et al
    A Huge Hepatocellular Carcinoma With Major Arteriovenous Shunt Successfully Treated With Chemoembolization Plus Lenvatinib Therapy Followed by Radiotherapy.
    Anticancer Res. 2025;45:1785-1792.
    PubMed     Abstract available
    
    
    
28. IZUTSU R, Osaki M, Seong H, Sato R, et al
    Hepatic Stellate Cells Activated by Cancer Cell-derived AMIGO2-containing Small Extracellular Vesicles Promote Cancer Cell Migration by Producing IL-8.
    Anticancer Res. 2025;45:1435-1446.
    PubMed     Abstract available
    
    
    
29. MASUDA T, Beppu T, Nagayama Y, Miyamoto H, et al
    Splenic Angiosarcoma and Numerous Liver Metastases Presenting the Kasabach-Merritt Phenomenon.
    Anticancer Res. 2025;45:1777-1784.
    PubMed     Abstract available
    
    
    March 2025
30. FUJISAWA T, Hojo H, Nakamura M, Makita K, et al
    Clinical Outcomes of Patients Receiving Stereotactic Body Radiotherapy Dose De-escalation for Hepatocellular Carcinoma at the Hepatic Hilum.
    Anticancer Res. 2025;45:1159-1169.
    PubMed     Abstract available
    
    
    
31. TANABE N, Saeki I, Yamaoka K, Kawaoka T, et al
    Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.
    Anticancer Res. 2025;45:1117-1125.
    PubMed     Abstract available
    
    
    
32. WHI W, Lee H, Hong JY, Kang W, et al
    (18)F-Fluorocholine PET/CT as an Imaging Biomarker in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
    Anticancer Res. 2025;45:1273-1280.
    PubMed     Abstract available
    
    
    
33. RYUNO Y, Abe T, Tsukahara K, Watanabe J, et al
    Stereotactic Body Radiotherapy Using CyberKnife for Metastatic Liver Tumors: A Single-center Retrospective Study.
    Anticancer Res. 2025;45:1127-1136.
    PubMed     Abstract available
    
    
    
34. WEISS TS, Buechler C
    Proprotein Convertase Subtilisin/Kexin Type 9 Induction in Hypercholesterinemic Patients With Primary and Metastatic Liver Tumors.
    Anticancer Res. 2025;45:1171-1180.
    PubMed     Abstract available
    
    
    February 2025
35. KAMIYA H, Imamura T, Ikoma H, Morimura R, et al
    Peak-postoperative Serum Transaminases Correlate With Post-hepatectomy Liver Failure and Inflow Occlusion After Laparoscopic Liver Resection.
    Anticancer Res. 2025;45:691-700.
    PubMed     Abstract available
    
    
    
36. DOKDUANG H, Jarernrat A, Titapun A, Sitthirak S, et al
    Characterization of Patient-derived Xenograft Models of Liver Fluke-associated Cholangiocarcinoma: From Establishment to Molecular Profiling.
    Anticancer Res. 2025;45:579-592.
    PubMed     Abstract available
    
    
    January 2025
37. KAWAMURA H, Imaizumi T, Miyakawa T, Nakao E, et al
    Development of a Prognostic Model for Stage IV Colorectal Cancer Using Metastatic Patterns.
    Anticancer Res. 2025;45:341-350.
    PubMed     Abstract available
    
    
    
38. KAWAMOTO M, Miyasaka Y, Kaida H, Watanabe M, et al
    Preoperative High FIB-4 Index and NFS Scores Predict a Reduced Incidence of Metachronous Liver Metastasis Following Pancreaticoduodenectomy.
    Anticancer Res. 2025;45:261-266.
    PubMed     Abstract available
    
    
    
39. ABE K, Fujioka S, Takano Y, Shirai Y, et al
    Lipoprotein(a) as a Predictor of Nonalcoholic Fatty Liver After Pancreatectomy.
    Anticancer Res. 2025;45:287-293.
    PubMed     Abstract available
    
    
    
40. ISHIHARA N, Komatsu S, Yano Y, Fujishima Y, et al
    Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:251-260.
    PubMed     Abstract available
    
    
    
41. PETRUCH N, Bolm L, Nebbia M, Arya S, et al
    How to Predict Recurrence After Resection of Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:189-199.
    PubMed     Abstract available
    
    
    December 2024
42. TATEISHI A, Okuma Y, Goto Y, Arakaki M, et al
    Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice.
    Anticancer Res. 2024;44:5501-5513.
    PubMed     Abstract available
    
    
    
43. LEE HH, Oh S, Kang H, Cho H, et al
    Blocking CXCR3B Expression Increases Tumor Aggressiveness in Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:5293-5301.
    PubMed     Abstract available
    
    
    
44. FU CY, Liao PA, Lin TH, Hsu FT, et al
    Imipramine-mediated Suppression of EGFR Signaling Attenuates Invasive and Progressive Abilities of Hepatocellular Carcinoma Cells.
    Anticancer Res. 2024;44:5323-5335.
    PubMed     Abstract available
    
    
    November 2024
45. MOON SU, Shah M, Thao TT, Woo HG, et al
    Long Non-coding RNA TPRG1-AS1 Interacts With CLTC in Liver Cancer Cells.
    Anticancer Res. 2024;44:4813-4824.
    PubMed     Abstract available
    
    
    October 2024
46. MATSUBARA K, Kobayashi T, Tadokoro T, Namba Y, et al
    The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection.
    Anticancer Res. 2024;44:4551-4559.
    PubMed     Abstract available
    
    
    September 2024
47. HOSOKAWA A, Tamura H, Ichihara A, Imamura N, et al
    Pathological Complete Response to Liver Metastasis With Pembrolizumab in a Previously Treated Patient With Microsatellite Instability-high Colorectal Cancer.
    Anticancer Res. 2024;44:4119-4125.
    PubMed     Abstract available
    
    
    
48. FURUKAWA K, Tsunematsu M, Haruki K, Onda S, et al
    Postoperative Nutritional Assessment of Laparoscopic Versus Open Partial Hepatectomy.
    Anticancer Res. 2024;44:3931-3936.
    PubMed     Abstract available
    
    
    
49. MOHRI K, Nagai H, Matsuda T, Igarashi Y, et al
    Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab.
    Anticancer Res. 2024;44:3919-3929.
    PubMed     Abstract available
    
    
    
50. FRACCAROLI A, Barnikel M, Scheubeck G, Buchstab O, et al
    Stealthy Invader: Clinically Inapparent But Rapidly Progressive Multifocal Metastatic Melanoma Unveiled as Root Cause of Liver Failure.
    Anticancer Res. 2024;44:4127-4132.
    PubMed     Abstract available
    
    
    
51. YAMAMOTO T, Ito T, Mizuno K, Yokoyama S, et al
    Impact of BMI and Body Composition on First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:4101-4111.
    PubMed     Abstract available
    
    
    
52. SEO J, Park M, Cho S
    NSC-38270 Exhibits Anti-invasive and Pro-apoptotic Effects on Hepatocellular Carcinoma Huh7 Cells.
    Anticancer Res. 2024;44:3857-3866.
    PubMed     Abstract available
    
    
    
53. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
    Simultaneously Detected Liver and Lung Metastases from Colorectal Carcinoma: A Potential Treatment Strategy.
    Anticancer Res. 2024;44:3945-3954.
    PubMed     Abstract available
    
    
    
54. TAMAKI N, Mori N, Takaki S, Tsuji K, et al
    Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:3913-3918.
    PubMed     Abstract available
    
    
    August 2024
55. SAKAI H, Goto Y, Fukutomi S, Arai S, et al
    Safety and Feasibility of Laparoscopic Anatomical Liver Resection for Hepatocellular Carcinoma: A Propensity Score-matched Study.
    Anticancer Res. 2024;44:3645-3653.
    PubMed     Abstract available
    
    
    
56. NAGATA T, Shakado S, Yamauchi E, Tokushige H, et al
    Tranilast Inhibits TRPV2 and Suppresses Fibrosis Progression and Weight Gain in a NASH Model Mouse.
    Anticancer Res. 2024;44:3593-3604.
    PubMed     Abstract available
    
    
    
57. GOTO Y, Niizeki T, Sakai H, Akashi M, et al
    A Multidisciplinary Therapeutic Approach Proposal for Huge Hepatocellular Carcinomas Exceeding 10 cm in Diameter.
    Anticancer Res. 2024;44:3629-3636.
    PubMed     Abstract available
    
    
    
58. HASHIMOTO K, Kanno H, Sakai H, Miyazaki D, et al
    Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score As a Predictor of Prognosis After Hepatectomy.
    Anticancer Res. 2024;44:3669-3678.
    PubMed     Abstract available
    
    
    
59. ARAI S, Sakai H, Akashi M, Goto Y, et al
    Clinicopathological Study of Resected and Recurrent Cases of Intrahepatic Intraductal Papillary Neoplasm of the Bile Duct.
    Anticancer Res. 2024;44:3623-3628.
    PubMed     Abstract available
    
    
    July 2024
60. KOMATSU S, Yano Y, Mimura T, Minami A, et al
    Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:3097-3103.
    PubMed     Abstract available
    
    
    
61. MIZUNO F, Imai N, Mizuno K, Yokoyama S, et al
    Clinical Outcomes of Use of the Porous Glass Membrane Pumping Emulsification Device During Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:3185-3191.
    PubMed     Abstract available
    
    
    June 2024
62. TOREN W, Sasor A, Ansari D, Andersson R, et al
    ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection.
    Anticancer Res. 2024;44:2597-2604.
    PubMed     Abstract available
    
    
    
63. IGARASHI Y, Haruki K, Furukawa K, Taniai T, et al
    Short-term Outcomes of Laparoscopic Versus Open Liver Resection in the Elderly: A Propensity Score-matched Analysis.
    Anticancer Res. 2024;44:2731-2736.
    PubMed     Abstract available
    
    
    
64. FUKUSHIMA NM, Adachi T, Tanaka T, Matsushima H, et al
    DCLK1 Expression and its Functional Significance in Intrahepatic Cholangiocarcinoma and Bil-IN Stage.
    Anticancer Res. 2024;44:2417-2424.
    PubMed     Abstract available
    
    
    May 2024
65. WAGNER D, Karitnig R, Wienerroither V, Hau HM, et al
    Sarcopenic Obesity Promotes Recurrence in Patients Undergoing Resection for Colorectal Liver Metastases (CRLM).
    Anticancer Res. 2024;44:2177-2183.
    PubMed     Abstract available
    
    
    
66. GON H, Komatsu S, Omiya S, Kido M, et al
    The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.
    Anticancer Res. 2024;44:2031-2038.
    PubMed     Abstract available
    
    
    
67. TSUNEMATSU M, Onda S, Shirai Y, Abe K, et al
    Strategies to Perform Emergency Laparoscopic Partial Liver Resection for Ruptured Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2171-2176.
    PubMed     Abstract available
    
    
    
68. SEO SH, Yu JI, Park HC, Yoo GS, et al
    Proton Beam Radiotherapy as a Curative Alternative to Radiofrequency Ablation for Newly Diagnosed Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2219-2230.
    PubMed     Abstract available
    
    
    
69. KOIZUMI A, Komatsu S, Omiya S, Yano Y, et al
    Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2055-2061.
    PubMed     Abstract available
    
    
    
70. IKUTA S, Aihara T, Kasai M, Nakajima T, et al
    Long-term Outcomes of Hepatic Resection Combined With Intraoperative Ablation Versus Hepatic Resection Alone for Multinodular Hepatocellular Carcinoma: Insights from a Single-center Study.
    Anticancer Res. 2024;44:2133-2140.
    PubMed     Abstract available
    
    
    
71. JUNG JY, Koh SA, Lee KH
    Cold-shock Domain Protein A (CSDA) Influences Hepatocyte Growth Factor-medicated Cell Proliferation and Metastasis in Gastric Cancer Cells.
    Anticancer Res. 2024;44:1973-1981.
    PubMed     Abstract available
    
    
    April 2024
72. OKUNO M, Hatano E, Tada M, Nishimura T, et al
    Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:1727-1737.
    PubMed     Abstract available
    
    
    
73. BEPPU T, Yamamura K, Masuda T, Miyamoto H, et al
    High-risk Patients With Colorectal Liver Metastases Assessed by the Beppu Score Can Have Excellent Survival Through Multidisciplinary Treatment Including Local Ablation.
    Anticancer Res. 2024;44:1533-1539.
    PubMed     Abstract available
    
    
    February 2024
74. ACS M, Herold Z, Neumann L, Slowik P, et al
    Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases: Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center.
    Anticancer Res. 2024;44:731-741.
    PubMed     Abstract available
    
    
    
75. KIM Y, Ajiki T, Ueda Y, Yoshida Y, et al
    Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites.
    Anticancer Res. 2024;44:613-619.
    PubMed     Abstract available
    
    
    
76. IMAOKA K, Ohira M, Shimomura M, Hattori M, et al
    Effect of Abdominal Aortic Calcification on Recurrence Following Initial Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2024;44:649-658.
    PubMed     Abstract available
    
    
    January 2024
77. ISHIKAWA T, Yamazaki S, Sato R, Jimbo R, et al
    Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
    Anticancer Res. 2024;44:361-368.
    PubMed     Abstract available
    
    
    
78. CHIBA N, Abe Y, Ando A, Nakagawa M, et al
    A Standardized Interrupted Parachute Suture Technique in Hepaticojejunostomy for Patients With Perihilar Cholangiocarcinoma.
    Anticancer Res. 2024;44:167-171.
    PubMed     Abstract available
    
    
    December 2023
79. TOMIOKA K, Aoki T, Tashiro Y, Kusano T, et al
    Laparoscopic Anatomical Liver Resection Using Liver Mapping of Incidental Indocyanine Green Fluorescence due to Cholestasis.
    Anticancer Res. 2023;43:5583-5588.
    PubMed     Abstract available
    
    
    
80. ZHANG XW, Mohr J, Halama N, Koschny R, et al
    Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
    Anticancer Res. 2023;43:5589-5596.
    PubMed     Abstract available
    
    
    November 2023
81. SHIOZAKI A, Kurashima K, Kudou M, Shimizu H, et al
    Cancer Stem Cells of Hepatocellular Carcinoma Are Suppressed by the Voltage-gated Calcium Channel Inhibitor Amlodipine.
    Anticancer Res. 2023;43:4855-4864.
    PubMed     Abstract available
    
    
    
82. SANO A, Sohda M, Hosoi N, Tateno K, et al
    Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2023;43:5205-5213.
    PubMed     Abstract available
    
    
    
83. OSHITA KO, Kobayashi T, Tadokoro T, Namba Y, et al
    Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:5189-5196.
    PubMed     Abstract available
    
    
    October 2023
84. KOBAYASHI K, Nagai H, Matsui T, Matsuda T, et al
    Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:4601-4609.
    PubMed     Abstract available
    
    
    
85. MUTO H, Kuzuya T, Kawabe N, Ohno E, et al
    Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2023;43:4673-4682.
    PubMed     Abstract available
    
    
    
86. GARRETT C, Cristaudo A, Barat S, Morris DL, et al
    Increased Incidence of Liver Metastases in Colorectal Versus Appendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival.
    Anticancer Res. 2023;43:4657-4662.
    PubMed     Abstract available
    
    
    
87. YANG JD, Yueh PF, Liao TL, Chen YT, et al
    Unlocking Synergistic Potential: Enhancing Regorafenib Efficacy in Hepatocellular Carcinoma Through Combination Therapy With 18beta-Glycyrrhetinic Acid.
    Anticancer Res. 2023;43:4403-4412.
    PubMed     Abstract available
    
    
    
88. WANG CC, Fan WL, Liu TT, Pang ST, et al
    Impact of Genomic Alterations on the Clinical Outcome of Patients With Hepatitis B-related Hepatocellular Carcinoma Receiving Curative Surgery: A Retrospective Cohort Study.
    Anticancer Res. 2023;43:4709-4722.
    PubMed     Abstract available
    
    
    
89. LEE YJ, Kim KC, Lee JM, Lim JM, et al
    Development of Polyethylene Glycol-based Hydrogels Optimized for In Vitro 3D Culture of HepG2 Hepatocarcinoma Cells.
    Anticancer Res. 2023;43:4373-4377.
    PubMed     Abstract available
    
    
    
90. YAMAMURA K, Beppu T, Miyata T, Mima K, et al
    Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy.
    Anticancer Res. 2023;43:4285-4293.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum